Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke

Abstract The discovery of immune checkpoint inhibitors (ICIs) such as programmed cell death protein 1 (PD-1) inhibitors, nivolumab and pembrolizumab, and programmed cell death ligand 1 (PD-L1) inhibitors, atezolizumab and durvalumab, has revolutionized the treatment of advanced non-small cell lung c...

Full description

Bibliographic Details
Main Authors: Lorenzo Belluomini, Francesco Fiorica, Antonio Frassoldati
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-01-01
Series:Oncology and Therapy
Subjects:
Combination treatment
Immune system
Immunotherapy
NSCLC
Radiotherapy
Online Access:http://link.springer.com/article/10.1007/s40487-019-0092-z

Internet

http://link.springer.com/article/10.1007/s40487-019-0092-z

Similar Items